Exact Sciences Corp. (EXAS) Volatility Spurs A Quest For Clarity

Currently, there are 181.36M common shares owned by the public and among those 179.64M shares have been available to trade.

The company’s stock has a 5-day price change of 15.65% and -0.32% over the past three months. EXAS shares are trading -0.32% year to date (YTD), with the 12-month market performance up to 11.29% higher. It has a 12-month low price of $56.05 and touched a high of $100.77 over the same period. EXAS has an average intraday trading volume of 2.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.22%, 18.96%, and 1.53% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Exact Sciences Corp. (NASDAQ: EXAS) shares accounts for 90.15% of the company’s 181.36M shares outstanding.

It has a market capitalization of $13.39B and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$1.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.29% over the week and 4.70% over the month.

Analysts forecast that Exact Sciences Corp. (EXAS) will achieve an EPS of -$0.46 for the current quarter, -$0.22 for the next quarter and $0.07 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.63 while analysts give the company a high EPS estimate of -$0.17. Comparatively, EPS for the current quarter was -$0.42 a year ago. Earnings per share for the fiscal year are expected to increase by 21.81%, and 114.05% over the next financial year.

Looking at the support for the EXAS, a number of firms have released research notes about the stock. The Benchmark Company stated their Buy rating for the stock in a research note on January 02, 2024, with the firm’s price target at $91. Guggenheim coverage for the Exact Sciences Corp. (EXAS) stock in a research note released on December 14, 2023 offered a Buy rating with a price target of $90. Wolfe Research was of a view on December 13, 2023 that the stock is Outperform, while Piper Sandler gave the stock Overweight rating on October 10, 2023, issuing a price target of $90. Bernstein on their part issued Outperform rating on September 28, 2023.

Most Popular

Related Posts